Aspire Private Capital’s TherapeuticsMD TXMD Stock Holding History

Aspire Private Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	-$2	–	593
2024 Q3	$2	Hold	1	–	–	﹤0.01%	681
2024 Q2	$2	Hold	1	–	–	﹤0.01%	692
2024 Q1	$2	Hold	1	–	–	﹤0.01%	723
2023 Q4	$2	Hold	1	–	–	﹤0.01%	705
2023 Q3	$3	Hold	1	–	–	﹤0.01%	701
2023 Q2	$4	Hold	1	–	–	﹤0.01%	674
2023 Q1	$4	Hold	1	–	–	﹤0.01%	654
2022 Q4	$6	Hold	1	–	–	﹤0.01%	653
2022 Q3	$0	Hold	1	–	–	﹤0.01%	662
2022 Q2	$0	Buy	+1	New	+$10	﹤0.01%	644
2022 Q1	–	Hold	0	–	–	–	672
2021 Q4	–	Hold	0	–	–	–	671
2021 Q3	–	Hold	0	–	–	–	638
2021 Q1	–	Hold	0	–	–	–	606
2020 Q4	–	Hold	0	–	–	–	532
2020 Q1	–	Hold	0	–	–	–	467
2019 Q4	–	Hold	0	–	–	–	536
2019 Q3	–	Hold	0	–	–	–	547
2019 Q2	–	Hold	0	–	–	–	633
2019 Q1	–	Hold	0	–	–	–	602
2018 Q4	–	Hold	0	–	–	–	560

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Aspire Private Capital's TXMD Position: Q4 2024 in Review

Aspire Private Capital sold out of TherapeuticsMD (TXMD) in Q4 2024, closing a stake of 1 share — an estimated $2 sold.

Aspire Private Capital first reported a position in TXMD in Q2 2022 and held it in 10 quarters. The position peaked at $6 in Q4 2022. 41 funds tracked by Wall St. Rank hold TXMD as of Q4 2024.

Aspire Private Capital reported no remaining TherapeuticsMD position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 1 TherapeuticsMD share in Q4 2024, an estimated $2.
Aspire Private Capital first reported a position in TherapeuticsMD in Q2 2022 and held it in 10 quarters.
Aspire Private Capital's TherapeuticsMD position peaked at $6 in Q4 2022.
41 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.